Below are summaries of recently published analyses from ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC over the last few months. Click on the shortened citations to access the publications.

Breast Cancer – Ductal carcinoma in situ (DCIS) is a non-life-threatening stage 0 breast cancer, characterized by the presence of abnormal cells in milk ducts. A key challenge is distinguishing between progressive versus non-progressive cases, highlighting the need for improved risk-stratification methods such as the one reported here. MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Slavkova KP. Radiology. April 2025

Breast Cancer – Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer. A Phase 2 Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study. Clark AS. Clin Can Res. July 2025

Cancer Control and Survivorship – In this nationwide survey, 80% of community oncology practices in NCORP report having processes in place to screen for and assist cancer patients with adverse health outcomes resulting from social and economic factors. Screening and Referral for Health-Related Social Needs and Financial Distress: Current Processes Among National Cancer Institute Community Oncology Research Program Practices. Banegas MP. JCO Oncol Pract. March 2025

Head and Neck Cancer – The only prospective, multi-center, randomized trial to examine chemotherapy before surgery for organ preservation in patients with nose and sinus cancer showed a striking improvement for patients that warrants a larger confirmatory study. Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. Saba NF. Clin Cancer Res. June 2025

Head and Neck Cancer – The largest prospective trial of a less intense treatment approach continues to show excellent survival across all subsites of T1-2 p16+ HPV+ throat cancer, regardless of smoking history. There is no evidence of increased late recurrence when post-operative radiation therapy is reduced from 60 to 50 Gy among intermediate-risk patients. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase 2 Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer. Burtness BA. J Clin Oncol. June 2025

Lung Cancer – Patients with extensive-stage small cell lung cancer benefited from the addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy. Randomized phase 2 clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Leal TA. Cancer. June 2025

Melanoma – Biospecimens from patients with high-risk melanoma who had participated in a previous trial (E1609) were analyzed for the expression levels of 31 tumor genes and 40 circulating blood biomarkers to assess their potential for predicting survival. Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Tarhini AA. Clin Cancer Res. June 2025